The global market for Human Milk Oligosaccharides (HMO) was estimated at US$236.1 Million in 2023 and is projected to reach US$565.6 Million by 2030, growing at a CAGR of 13.3% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
Global Human Milk Oligosaccharides (HMO) Market - Key Trends and Drivers Summarized
Why Are Human Milk Oligosaccharides (HMO) Essential for Infant Nutrition?
Human Milk Oligosaccharides (HMOs) are complex carbohydrates found in human breast milk that play a crucial role in infant health and development. HMOs serve as prebiotics, promoting the growth of beneficial gut bacteria, which supports the infant's immune system and overall digestive health. Although HMOs are not digestible by infants, they provide a range of benefits, including protecting against pathogens and reducing the risk of infections. In recent years, the infant formula industry has recognized the importance of HMOs in mimicking the benefits of breast milk, leading to the incorporation of synthetic HMOs in formula products to support the growth and development of formula-fed infants.How Are Technological Advancements Shaping the Human Milk Oligosaccharides Market?
The market for Human Milk Oligosaccharides has grown significantly due to advancements in biotechnology that allow for the large-scale production of synthetic HMOs. Using microbial fermentation techniques, manufacturers can produce HMOs identical to those found in human milk, making it possible to add these compounds to infant formula. This development has been transformative, as it enables formula-fed infants to receive some of the immune-boosting and digestive benefits previously only available through breastfeeding. Furthermore, ongoing research into the diverse types of HMOs - over 200 variations - has opened new opportunities for creating targeted infant nutrition products that support specific health outcomes, such as improved gut health or enhanced immune function.How Do Market Segments Define the Growth of the Human Milk Oligosaccharides Market?
Types of HMOs include 2'-Fucosyllactose (2'-FL), Lacto-N-neotetraose (LNnT), and other complex oligosaccharides, with 2'-FL being the most commonly used in infant formula due to its proven health benefits and ease of production. Applications of HMOs are primarily found in infant nutrition, but they are also being explored for adult nutrition and dietary supplements due to their potential benefits in gut health and immune function. Distribution channels include supermarkets, pharmacies, and online platforms, with online sales seeing rapid growth as e-commerce expands in the infant nutrition sector. The market is also expanding geographically, with North America and Europe leading, while Asia-Pacific is experiencing significant growth due to rising awareness of infant nutrition.What Factors Are Driving the Growth in the Human Milk Oligosaccharides Market?
The growth in the Human Milk Oligosaccharides market is driven by several factors, including increasing awareness of the health benefits of HMOs, advancements in biotechnology for large-scale production, and rising demand for premium infant nutrition products. As parents become more informed about the importance of gut health and immune support in early development, demand for HMO-enriched formula has surged. Technological innovations in microbial fermentation have made the production of HMOs more cost-effective, allowing manufacturers to include these compounds in a wider range of products. Additionally, the growing middle-class population in emerging markets, coupled with rising disposable income, has boosted demand for high-quality, science-backed infant nutrition products, further fueling the expansion of the HMO market.Key Insights:
- Market Growth: Understand the significant growth trajectory of the Infant Formula Application segment, which is expected to reach US$444.0 Million by 2030 with a CAGR of a 12.9%. The Functional Food & Beverage Application segment is also set to grow at 17.1% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, which was estimated at $61.2 Million in 2023, and China, forecasted to grow at an impressive 17.2% CAGR to reach $137.6 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Human Milk Oligosaccharides (HMO) Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Human Milk Oligosaccharides (HMO) Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Human Milk Oligosaccharides (HMO) Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players in the Human Milk Oligosaccharides (HMO) market such as Basf SE, Dextra Laboratories Limited, DuPont Nutrition & Health, Elicityl SA, Glycom A/S and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 53 companies featured in this Human Milk Oligosaccharides (HMO) market report include:
- Basf SE
- Dextra Laboratories Limited
- DuPont Nutrition & Health
- Elicityl SA
- Glycom A/S
- Glycosyn LLC
- Inbiose
- Jennewein Biotechnologie GmbH
- Medolac Laboratories
- Nestlé Health Science
- ZuChem, Inc.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISSOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
SPAIN
RUSSIA
REST OF EUROPE
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned
- Basf SE
- Dextra Laboratories Limited
- DuPont Nutrition & Health
- Elicityl SA
- Glycom A/S
- Glycosyn LLC
- Inbiose
- Jennewein Biotechnologie GmbH
- Medolac Laboratories
- Nestlé Health Science
- ZuChem, Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 99 |
Published | December 2024 |
Forecast Period | 2023 - 2030 |
Estimated Market Value ( USD | $ 236.1 Million |
Forecasted Market Value ( USD | $ 565.6 Million |
Compound Annual Growth Rate | 13.3% |
Regions Covered | Global |
No. of Companies Mentioned | 11 |